Fund shareholders of Dyne Therapeutics Inc
ISIN US26818M1080 · United States
- Fund shareholders
- 226
- Of which ETFs
- 50 176 other funds
- Value held
- ≈ 1.1B $ 1.1B $ · 141.5K €
- Share of capital
- 33.5 % of 186.7M shares on Jul 24, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Multimanager Aggressive Equity Portfolio EQ Advisors Trust | 1,400 | 25.4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Nuveen Life Stock Index Fund TIAA-CREF Life Funds | 1,256 | 22.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| JPMorgan Fundamental Data Science Small Core ETF J.P. Morgan Exchange-Traded Fund Trust | 1,117 | 20.3K $ | 0.27 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Harbor Active Small Cap Growth ETF Harbor ETF Trust | 840 | 14.7K $ | 0.40 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 801 | 14.1K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| BlackRock Advantage SMID Cap V.I. Fund BlackRock Variable Series Funds, Inc. | 780 | 14.1K $ | 0.01 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 735 | 13.3K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Dimensional US Vector Equity ETF Dimensional ETF Trust | 720 | 12.6K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 626 | 11.3K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Innovator U.S. Small Cap Managed 10 Buffer ETF Innovator ETFs Trust | 462 | 8.1K $ | 0.11 % | 0.00 % | as of Apr 30, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 446 | 8.1K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Flex Small Cap Focused Index Fund Fidelity Salem Street Trust | 404 | 7.1K $ | 0.05 % | 0.00 % | as of Apr 30, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 337 | 6.1K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 322 | 5.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Small Company Value Portfolio Wilshire Mutual Funds Inc | 290 | 5.3K $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 283 | 5.1K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 243 | 4.3K $ | 0.05 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST | 192 | 3.5K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 192 | 3.4K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 172 | 3.1K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 127 | 2K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 110 | 2K $ | 0.07 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 37 | 577.9 $ | 0.05 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 33 | 598.3 $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs MSCI World Private Equity Return Tracker ETF Goldman Sachs ETF Trust | 3 | 46.9 $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 141.5K € | 0.17 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| iShares Neuroscience and Healthcare ETF iShares Trust | 2.36 % | as of Apr 30, 2026 ↗ |
| Wasatch Ultra Growth Fund WASATCH FUNDS TRUST | 1.96 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Health Care ETF T. Rowe Price Exchange-Traded Funds, Inc. | 1.88 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Institutional Small-Cap Stock Fund T. Rowe Price Equity Funds, Inc. | 1.59 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Small-Cap Stock Fund, Inc. T. ROWE PRICE SMALL-CAP STOCK FUND, INC. | 1.58 % | as of Mar 31, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 1.12 % | as of Apr 30, 2026 ↗ |
| T. Rowe Price Small-Cap Value Fund, Inc. T. ROWE PRICE SMALL-CAP VALUE FUND, INC. | 0.91 % | as of Mar 31, 2026 ↗ |
| Janus Henderson Global Life Sciences Fund JANUS INVESTMENT FUND | 0.88 % | as of Mar 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 0.88 % | as of Apr 30, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.84 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 225 | +2 | 62,610,298 | +22.8 % |
| 2026Q1 | 223 | +16 | 51,004,170 | +38.9 % |
| 2025Q4 | 207 | +13 | 36,727,646 | +21.3 % |
| 2025Q3 | 194 | -7 | 30,273,414 | +2.7 % |
| 2025Q2 | 201 | -11 | 29,477,927 | +2.7 % |
| 2025Q1 | 212 | -21 | 28,711,355 | -12.5 % |
| 2024Q4 | 233 | +23 | 32,817,223 | +27.1 % |
| 2024Q3 | 210 | +32 | 25,811,309 | +34.6 % |
| 2024Q2 | 178 | +20 | 19,177,088 | +48.7 % |
| 2024Q1 | 158 | -7 | 12,892,346 | +13.5 % |
| 2023Q4 | 165 | 11,359,327 |
Institutional managers
220 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30,785,801 | 558.1K $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 13,647,376 | 247.4M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 11,699,870 | 212.1M $ | as of Mar 31, 2026 |
| Atlas Venture Life Science Advisors, LLC | 9,130,465 | 165.5M $ | as of Mar 31, 2026 |
| FMR LLC | 8,908,980 | 161.5M $ | as of Mar 31, 2026 |
| Orbis Allan Gray Ltd | 6,762,231 | 122.6M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 6,653,746 | 120.6M $ | as of Mar 31, 2026 |
| PERCEPTIVE ADVISORS LLC | 4,668,839 | 84.6M $ | as of Mar 31, 2026 |
| FCPM III SERVICES B.V. | 4,644,386 | 84.2M $ | as of Mar 31, 2026 |
| TCG Crossover Management, LLC | 4,615,144 | 83.7M $ | as of Mar 31, 2026 |
| Vestal Point Capital, LP | 4,000,000 | 72.5M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,504,114 | 63.5M $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 3,253,473 | 55.6M $ | as of Mar 31, 2026 |
| ARMISTICE CAPITAL, LLC | 3,175,110 | 57.6M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 3,153,082 | 57.2M $ | as of Mar 31, 2026 |
| ORBIMED ADVISORS LLC | 2,917,884 | 52.9M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2,328,373 | 42.2K $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 2,229,125 | 40.4M $ | as of Mar 31, 2026 |
| Venrock Adviser, LLC | 2,173,913 | 39.4M $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 2,009,082 | 36.4M $ | as of Mar 31, 2026 |
| Deep Track Capital, LP | 2,000,000 | 36.3M $ | as of Mar 31, 2026 |
| SAMLYN CAPITAL, LLC | 1,922,543 | 34.9M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,723,116 | 31.2M $ | as of Mar 31, 2026 |
| BRAIDWELL LP | 1,681,998 | 30.5M $ | as of Mar 31, 2026 |
| Palo Alto Investors LP | 1,652,972 | 30M $ | as of Mar 31, 2026 |
Declared shareholders of Dyne Therapeutics Inc
There are 3 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.70 % | 30,785,801 | as of Mar 31, 2026 · SCHEDULE 13G |
| JANUS HENDERSON GROUP PLC | 8.30 % | 13,647,376 | as of Mar 31, 2026 · SCHEDULE 13G |
| FMR LLC and 1 other | 5.40 % | 8,908,980 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of Dyne Therapeutics Inc". https://titelia.com/en/stocks/dyne-therapeutics-inc-US26818M1080